Published in PLoS One on June 25, 2008
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines (2009) 1.83
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis (2012) 1.82
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther (2009) 1.69
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci U S A (2008) 1.59
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLoS Pathog (2011) 1.52
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin. PLoS One (2009) 1.20
H5N1 vaccines in humans. Virus Res (2013) 1.16
Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol (2011) 1.13
A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine (2011) 1.12
Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development. Proc Natl Acad Sci U S A (2010) 1.10
Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola. Mol Ther (2013) 1.05
New vaccines against influenza virus. Clin Exp Vaccine Res (2013) 1.04
GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One (2010) 1.01
Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques. Vaccine (2010) 0.98
Evolution of H3N2 influenza virus in a guinea pig model. PLoS One (2011) 0.97
Activated CD4+CCR5+ T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques. Proc Natl Acad Sci U S A (2014) 0.95
Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving target. Expert Rev Mol Med (2010) 0.93
Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther (2011) 0.92
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus. Virol J (2010) 0.91
Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods (2012) 0.90
Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin Vaccine Immunol (2011) 0.90
Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines. Viruses (2012) 0.89
Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques. PLoS One (2012) 0.87
Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One (2011) 0.87
High dose of plasmid IL-15 inhibits immune responses in an influenza non-human primates immunogenicity model. Virology (2009) 0.86
DNA vaccines in veterinary use. Expert Rev Vaccines (2009) 0.86
HIV-1 Env DNA vaccine plus protein boost delivered by EP expands B- and T-cell responses and neutralizing phenotype in vivo. PLoS One (2013) 0.85
Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccin (2010) 0.85
Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum Vaccin Immunother (2012) 0.84
Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus. J Infect Dis (2016) 0.83
Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method. Respir Res (2011) 0.83
Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus. Clin Vaccine Immunol (2009) 0.83
Targets for the induction of protective immunity against influenza a viruses. Viruses (2010) 0.82
The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014. Antiviral Res (2015) 0.82
Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccines (Basel) (2015) 0.81
Co-Administration of Molecular Adjuvants Expressing NF-Kappa B Subunit p65/RelA or Type-1 Transactivator T-bet Enhance Antigen Specific DNA Vaccine-Induced Immunity. Vaccines (Basel) (2014) 0.80
Novel synthetic plasmid and Doggybone DNA vaccines induce neutralizing antibodies and provide protection from lethal influenza challenge in mice. Hum Vaccin Immunother (2015) 0.80
A single dose of DNA vaccine based on conserved H5N1 subtype proteins provides protection against lethal H5N1 challenge in mice pre-exposed to H1N1 influenza virus. Virol J (2010) 0.79
Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses. Future Virol (2013) 0.78
Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver. Cancer Gene Ther (2012) 0.78
New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus. PLoS One (2013) 0.77
Protein engineering strategies for the development of viral vaccines and immunotherapeutics. FEBS Lett (2013) 0.76
Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis. PLoS One (2016) 0.75
Centralized Consensus Hemagglutinin Genes Induce Protective Immunity against H1, H3 and H5 Influenza Viruses. PLoS One (2015) 0.75
A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin. Hum Vaccin Immunother (2015) 0.75
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med (2006) 9.73
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet (2006) 5.72
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet (2006) 4.22
Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res (2004) 3.95
Gene transfer into muscle by electroporation in vivo. Nat Biotechnol (1998) 3.89
Cell-mediated protection in influenza infection. Emerg Infect Dis (2006) 3.62
CD4 T cell-mediated protection from lethal influenza: perforin and antibody-mediated mechanisms give a one-two punch. J Immunol (2006) 2.99
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005) 2.82
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine (2006) 2.59
Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol (2000) 2.54
Avian influenza virus exhibits rapid evolutionary dynamics. Mol Biol Evol (2006) 2.41
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis (2002) 1.88
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine (2004) 1.74
Rapid-response vaccines--does DNA offer a solution? Nat Biotechnol (2005) 1.67
Influenza virus infections and immunity: a review of human and animal models. Lab Anim Sci (1992) 1.65
Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol (2006) 1.63
Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52
Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 1.40
Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int Immunol (2000) 1.35
Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine (2002) 1.34
Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine (2007) 1.26
From plasmids to protection: a review of DNA vaccines against infectious diseases. Int Rev Immunol (2006) 1.21
Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol (2000) 1.13
Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation. Vaccine (2000) 0.97
Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine (2005) 0.94
Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH. Viral Immunol (2005) 0.94
Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine (2008) 0.93
Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol (2005) 0.90
A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes Infect (2005) 0.87
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65
DNA-binding specificities of human transcription factors. Cell (2013) 5.14
Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J (2010) 4.78
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Multiplexed massively parallel SELEX for characterization of human transcription factor binding specificities. Genome Res (2010) 3.46
MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science (2011) 3.17
Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med (2012) 2.98
Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis (2004) 2.90
Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev (2006) 2.77
Mice lacking a Myc enhancer that includes human SNP rs6983267 are resistant to intestinal tumors. Science (2012) 2.58
Lethal influenza virus infection in macaques is associated with early dysregulation of inflammatory related genes. PLoS Pathog (2009) 2.44
Molecular determinants of Ebola virus virulence in mice. PLoS Pathog (2006) 2.44
Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J Virol (2004) 2.34
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
mAbs and Ad-vectored IFN-α therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms. Sci Transl Med (2013) 2.10
Proteolytic activation of the 1918 influenza virus hemagglutinin. J Virol (2009) 2.05
Chikungunya: a potentially emerging epidemic? PLoS Negl Trop Dis (2010) 2.05
Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis (2005) 2.03
Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci Rep (2013) 2.01
Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help. J Immunol (2005) 2.01
Ebola virus VP40 late domains are not essential for viral replication in cell culture. J Virol (2005) 1.97
Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine (2007) 1.88
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine (2008) 1.87
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog (2010) 1.81
Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol (2009) 1.77
Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood (2009) 1.75
Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther (2009) 1.69
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One (2008) 1.67
Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine (2008) 1.67
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis (2013) 1.63
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A (2007) 1.60
Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo. Hum Gene Ther (2009) 1.57
HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine (2005) 1.56
Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol (2014) 1.52
Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine (2007) 1.52
An optimized SIV DNA vaccine can serve as a boost for Ad5 and provide partial protection from a high-dose SIVmac251 challenge. Vaccine (2012) 1.52
Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. J Virol (2010) 1.47
Reconstruction and function of ancestral center-of-tree human immunodeficiency virus type 1 proteins. J Virol (2007) 1.46
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine (2005) 1.45
Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses (2005) 1.45
Anti-tumor activity mediated by protein and peptide transduction of HIV viral protein R (Vpr). Cancer Biol Ther (2009) 1.44
Assessment of the efficacy of commercially available and candidate vaccines against a pandemic H1N1 2009 virus. J Infect Dis (2010) 1.43
Molecular genetic relationship of the 3' untranslated region among Thai dengue-3 virus, Bangkok isolates, during 1973-2000. DNA Cell Biol (2009) 1.42
Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells. Am J Physiol Cell Physiol (2003) 1.42
Macaque model for severe acute respiratory syndrome. J Virol (2004) 1.41
Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther (2006) 1.41
Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther (2007) 1.40
An optimized ultraviolet-A light photodetector with wide-range photoresponse based on ZnS/ZnO biaxial nanobelt. Adv Mater (2012) 1.39
Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther (2002) 1.39
DNA vaccines: developing new strategies to enhance immune responses. Immunol Res (2008) 1.36
Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. J Virol (2004) 1.34
Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine (2008) 1.34
HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem (2002) 1.31
Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. J Clin Invest (2015) 1.30
Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis (2002) 1.30
DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge. Proc Natl Acad Sci U S A (2009) 1.30
Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques. Mol Ther (2010) 1.28
Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine (2008) 1.28
T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS (2002) 1.27
Quantitative proteomic analyses of influenza virus-infected cultured human lung cells. J Virol (2010) 1.27
MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem (2007) 1.27
Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine (2007) 1.26
A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog (2012) 1.26
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A (2013) 1.25
Carbonic anhydrase-related protein VIII deficiency is associated with a distinctive lifelong gait disorder in waddles mice. Genetics (2005) 1.25
Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis (2011) 1.25